New classificati on of Ph negative chronic myeloproliferative ne oplasi as

1. Swerdlow SH, Campo E, Hartus NL et al. WHO Classificati on of Tumo urs of Haematopo i etic and Lympho id Tissues. Lyon: IARC Press 2008.

2. Adam Z, Vorlíček J, Vaníček J et al. Di agnostické a léčebné postupy u maligních chorob. Druhé, aktu alizované a doplněné vydání. Praha: Grada Publishing 2004.

3. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8– 29.

4. Kralovics R, Passamonti F, Buser AS et al. A gain‑of- uncti on mutati on of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779– 1790.

5. Baxter EJ, Scott LM, Campbell PJ et al. Aquired mutati on of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054– 1061.

6. Levine RL, Wadleigh M, Co ols J et al. Activating mutati on in the tyrosine kinase JAK2 in polycythemi a vera, essenti al thrombocythemi a, and myelo id metaplasi a with myelofibrosis. Cancer Cell 2005; 7: 387– 397.

7. James C, Ugo V, Le Co uédic JP et al. A unique clonal JAK2 mutati on le ading to constitutive signalling ca use of polycythemi a vera. Nature 2005; 434: 1144– 1148.

8. Zhao R, Xing S, Li Z et al. Identificati on of an acquired JAK2 mutati on in polycythemi a vera. J Bi ol Chem 2005; 280: 22788– 22792.

9. Levine RL, Lori a ux M, Huntly BJ et al. The JAK2V617F activating mutati on occurs in chronic myelomonocytic le ukemi a and acute myelo id le ukemi a, but not in acute lymphoblastic le ukemi a or chronic lymphocytic le ukemi a. Blo od 2005; 106: 3377– 3379.

10. Remacha AF, Nomdedéu JF, Puget G et al. Occurence of the JAK2 V617F mutati on in the WHO provisi onal entity: myelodysplastic/ myeloproliferative dise ase, unclassifi able- refractory anemi a with ringed sideroblasts associ ated with marked thrombocytosis. Haematologica 2006; 91: 719– 720.

11. Szpurka H, Ti u R, Murugesan G et al. Refractory anemi a with ringed sideroblasts associ ated with marked thrombocytosis (RARS-T), another myeloproliferative conditi on characterized by JAK2 V617F mutati on. Blo od 2006; 108: 2173– 2181.

12. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutati ons in polycythemi a vera and idi opatic erytrocytosis. N Engl J Med 2007; 356: 459– 468.

13. Pardanani AD, Levine RL, LaSho TL et al. MPL515 mutati ons in myeloproliferative and other myelo id disorders: a study of 1182 pati ents. Blo od 2006; 108: 3472– 3476.

14. Yo u W, Weisbrot IM. Chronic ne utrophilic le ukaemi a. Report of two cases and rewi ew of the literature. Am J Clin Pathol 1979; 72: 233– 242.

15. Marchi oli R, Finazzi G, Landolfi R et al. Vascular and ne oplastic risk in large cohort of pati ents with polycythemi a vera. J Clin Oncol 2005; 23: 2224– 2232.

16. Andri e ux JL, Demory JL. Karyotype and molecular cytogenetic studi es in polycythemi a vera. Curr Hematol Rep 2005; 4: 224– 229.

17. Andréasson B, Swolin B, Kutti J et al. Pati ents with idi opathic myelofibrosis show incre ased CD34+ cell concentrati ons in peripheral blo od compared to pati ents with polycythaemi a vera and essenti al thrombocythaemi a. Eur J Haematol 2002; 68: 189– 193.

18. Cervantes F, Dupri ez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the Internati onal Gro up for Myelofibrosis Rese arch and Tre atment. Blo od 2009; 113: 2895– 2901.

19. Finazzi G, Harrison C. Essenti al thrombocythaemi a. Semin Hematol 2005; 42: 230– 238.

20. Tefferi A, Pardanani A. Clinical, genetic, and therape utic insights into systemic mast cell dise ase. Curr Opin Hematol 2004; 11: 58– 64.

21. Brunning RD, McKenna RW, Rossai J et al. Systemic mastocytosis. Extracutane o us manifestati ons. Am J Surg Pathol 1983; 7: 425– 438.

22. Tefferi A, Patnaik MM, Pardanani A. Eosinophili a: secondary, clonal and idi opatic. Br J Haematol 2006; 133: 468– 492.